Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form. It is one of the most common complication of pregnancy and a major cause of morbidity, long-term debility, and death among both the baby and the mother. Preeclampsia generally occurs after the 20th week of pregnancy, caused by mixture of elevated blood pressure and protein in the urine (proteinuria). Severe headache, blurring vision, heartburn, and swelling of the face are the common symptoms of preeclampsia. According to a report published by the Center for Maternal and Child Enquiries in the U.K., preeclampsia was ranked as the second most common direct cause of maternal death between 2006 and 2008. In Asia and Africa, one in 10 deaths is associated with pregnancy related hypertension. However, majority of deaths caused by eclampsia or preeclampsia are preventable through proper diagnosis and effective care of the patients. Preeclampsia accounts for about 20% of total maternal deaths and is the third leading cause of maternal mortality in the U.S.
The preeclampsia diagnostics market can be segmented into test type, instrument, and end-user. Based on test type, the global preeclampsia diagnostics market can be classified into biomarker and immunoassay. The immunoassay (ELISA) segment can be further divided into Elecsys PIGF/sFLT-1, and DELFIA Xpress PlGF kit2. The immunoassay test provides early and specific diagnosis of preeclampsia. The biomarker segment can be further categorized into placental growth factor (PlGF), vascular endothelial growth factor (VEGF), soluble endoglin (sEng), soluble Fms-like tyrosine kinase -1(sFlt-1), pregnancy associated plasma protein-A (PAPP-A), placental protein 13(PP-13), neutrophil gelatinase-associated lipocalin (NGAL), and others.
Based on instrument, the global preeclampsia diagnostics market can be segmented into Victor2 D Instrument, AutoDELFIA immunoassay system for prenatal screening, and others. In terms of end-user, the global preeclampsia diagnostics market can be divided into hospitals, specialty clinics, diagnostics laboratories, research centers, and others. The diagnostics laboratories segment constituted major market share in 2016. The specialty clinics segment is expected to register high growth during the forecast period. Good service provided by the specialty clinics and diagnostics laboratories, and availability of instruments are estimated to propel the market during the forecast period. Other factors that drive the global preeclampsia diagnostics market are rise in prevalence of pregnancy related hypertension and recent developments in diagnostics kits.
Geographically, the global preeclampsia diagnostics market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to account for high market share of the global preeclampsia diagnostics market, owing to the developments in diagnostic tests and increase in prevalence of pregnancy related diseases in the region. Europe accounted for major market share in 2016, owing to rise in incidence of preeclampsia in the region. Governments of countries in Europe are focused on launching awareness programs for prevention of preeclampsia, and diagnostics and treatment of women suffering from the disease. In 2012, the European Foundation for the Care of Newborn Infants (EFCNI), announced collaboration with PerkinElmer, a global leader focused on improving the health and safety of people and environment. Rise in prevalence of the disease is expected to boost the growth of the preeclampsia diagnostics market during the forecast period. The market in Asia Pacific is expected to register a high CAGR during the forecast period. Rise in demand for newer and advanced diagnostics tools, increase in research and development programs, and participation of governments in creating awareness about the disease are expected to boost the growth of the market in the region during the forecast period.
Key players in the global preeclampsia diagnostics market are Roche, DRG INSTRUMENTS GMBH, PerkinElmer Inc., Diabetomics, Inc., Siemens AG, LionsGate Technologies Inc., among others. Roche was the first company that developed immunoassay for diagnosis of preeclampsia. Growing demand for preeclampsia screening due to rise in awareness about the disease is expected to propel the global preeclampsia market during the forecast period.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.